The association between statin pre-treatment and LDL Levels on the rate of STEMI presentation: data from the ACS Israeli Survey (ACSIS) 2008–2018
Abstract Background ST-elevation myocardial infarction (STEMI) mostly occurs as a result of vulnerable coronary artery plaque rupture. Constituting hypolipidemic and pleiotropic effects, statins stabilize coronary artery plaque and may prevent STEMI events. Purpose To determine the association betwe...
Saved in:
Published in | European heart journal Vol. 41; no. Supplement_2 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.11.2020
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Background
ST-elevation myocardial infarction (STEMI) mostly occurs as a result of vulnerable coronary artery plaque rupture. Constituting hypolipidemic and pleiotropic effects, statins stabilize coronary artery plaque and may prevent STEMI events.
Purpose
To determine the association between statin pre-treatment and its intensity, low-density-lipoprotein cholesterol (LDL-C) levels and presentation of patients with an ACS (STEMI vs. NSTEMI/unstable angina [UAP]).
Methods
Data was drawn from the Acute Coronary Syndrome Israeli Survey (ACSIS), a biennial prospective survey of ACS patients hospitalized in all CCU/Cardiology departments during 2008–2018. The rate of STEMI vs NSTEMI/UAP at the time of presentation was calculated by LDL-C levels on admission, stratified to 5 subgroups (<50, 50–69, 70–100, 101–130 and >130 mg/dl) and the use of statins, including statin intensity prior to the index ACS event.
Results
Among 5,103 patients, 875 (17%) were pre-treated with high intensity statin (HIST), 1,389 (27%) with low intensity statin (LIST), and 2,839 (56%) were statin naive patients. Statin-pre-treated patients were older, more likely to suffer from co-morbidities and cardiovascular diseases and were more often pre-treated with anti-platelets.
The proportion of patients presenting with STEMI vs. NSTEMI/UAP was significantly lower among HIST vs. LIST vs. statin naive patients (31.0%, 37.8%, 54.0%, respectively, p for trend <0.001). At each LDL-C level, the proportion of STEMI was significantly lower among HIST vs. LIST vs. statin naive patients. Multivariate analysis adjusting for pertinent variables including propensity score for statin use, revealed that HIST was independently associated with lower STEMI presentation, but LDL-C<70 and LIST were not.
Conclusions
Among patients admitted with ACS, pre-treatment with high intensity statin but not LDL-C level, was independently associated with a lower probability of presenting with STEMI.
Funding Acknowledgement
Type of funding source: None |
---|---|
AbstractList | Abstract
Background
ST-elevation myocardial infarction (STEMI) mostly occurs as a result of vulnerable coronary artery plaque rupture. Constituting hypolipidemic and pleiotropic effects, statins stabilize coronary artery plaque and may prevent STEMI events.
Purpose
To determine the association between statin pre-treatment and its intensity, low-density-lipoprotein cholesterol (LDL-C) levels and presentation of patients with an ACS (STEMI vs. NSTEMI/unstable angina [UAP]).
Methods
Data was drawn from the Acute Coronary Syndrome Israeli Survey (ACSIS), a biennial prospective survey of ACS patients hospitalized in all CCU/Cardiology departments during 2008–2018. The rate of STEMI vs NSTEMI/UAP at the time of presentation was calculated by LDL-C levels on admission, stratified to 5 subgroups (<50, 50–69, 70–100, 101–130 and >130 mg/dl) and the use of statins, including statin intensity prior to the index ACS event.
Results
Among 5,103 patients, 875 (17%) were pre-treated with high intensity statin (HIST), 1,389 (27%) with low intensity statin (LIST), and 2,839 (56%) were statin naive patients. Statin-pre-treated patients were older, more likely to suffer from co-morbidities and cardiovascular diseases and were more often pre-treated with anti-platelets.
The proportion of patients presenting with STEMI vs. NSTEMI/UAP was significantly lower among HIST vs. LIST vs. statin naive patients (31.0%, 37.8%, 54.0%, respectively, p for trend <0.001). At each LDL-C level, the proportion of STEMI was significantly lower among HIST vs. LIST vs. statin naive patients. Multivariate analysis adjusting for pertinent variables including propensity score for statin use, revealed that HIST was independently associated with lower STEMI presentation, but LDL-C<70 and LIST were not.
Conclusions
Among patients admitted with ACS, pre-treatment with high intensity statin but not LDL-C level, was independently associated with a lower probability of presenting with STEMI.
Funding Acknowledgement
Type of funding source: None |
Author | Glikson, M Moriel, M Gottlieb, S Iakobishvili, Z Asher, E Samuel, T.Y Dadon, Z Steinmetz, Y |
Author_xml | – sequence: 1 givenname: Z surname: Dadon fullname: Dadon, Z organization: Shaare Zedek Medical Center, Jerusalem, Israel – sequence: 2 givenname: M surname: Moriel fullname: Moriel, M organization: Shaare Zedek Medical Center, Jerusalem, Israel – sequence: 3 givenname: T.Y surname: Samuel fullname: Samuel, T.Y organization: Shaare Zedek Medical Center, Jerusalem, Israel – sequence: 4 givenname: Y surname: Steinmetz fullname: Steinmetz, Y organization: Shaare Zedek Medical Center, Jerusalem, Israel – sequence: 5 givenname: E surname: Asher fullname: Asher, E organization: Shaare Zedek Medical Center, Jerusalem, Israel – sequence: 6 givenname: Z surname: Iakobishvili fullname: Iakobishvili, Z organization: Clalit Health services, Tel Aviv, Israel – sequence: 7 givenname: M surname: Glikson fullname: Glikson, M organization: Shaare Zedek Medical Center, Jerusalem, Israel – sequence: 8 givenname: S surname: Gottlieb fullname: Gottlieb, S organization: Shaare Zedek Medical Center, Jerusalem, Israel |
BookMark | eNotkL1OwzAUhS1UJErhBZjuCEOK7cROwlaVApWCGJKBLbLTazVVm1S2KerGO_QNeRLc0uX-6Zyjq--aDLq-Q0LuGB0zmsePuFw1bahK5Ykcx5TyCzJkgvMol4kYkCFluYikzD6vyLVzK0ppJpkckkO1RFDO9U2rfNt3oNF_I3bgfNg72FqMvEXlN9h5UN0CiucCCtzh2kGQ-2C3yiP0Bspq9j4_OlzQntKeYKG8AmP7zUk5mZYwd1bhuoXyy-5wD_fhNi8fgIePfn8OnLLshlwatXZ4e-4jUr3MqulbVHy8zqeTImoyxiMhTJ6iFCzVzKRCMs24pnyhm4zLOGGKasN0k6BUkjbUCKRhNFSkOjPM5PGI8P_YxvbOWTT11rYbZfc1o_WRan2iWp-p1keq8R-x3m9J |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1093/ehjci/ehaa946.3002 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1522-9645 |
ExternalDocumentID | 10_1093_ehjci_ehaa946_3002 |
GroupedDBID | --- -E4 .2P .I3 .XZ .ZR 08P 0R~ 18M 1TH 29G 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 70D AABZA AACZT AAJKP AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AASNB AAUAY AAUQX AAVAP AAYXX ABEUO ABIXL ABKDP ABNHQ ABNKS ABOCM ABPTD ABQLI ABQNK ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHXPO AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCGUY BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CITATION CS3 CZ4 DAKXR DIK DILTD D~K E3Z EBS EE~ EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M41 M49 MHKGH ML0 N9A NGC NOMLY NOYVH NU- O9- OAUYM OAWHX OB3 OCZFY ODMLO OGROG OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX ROZ RUSNO RW1 RXO SEL TCURE TEORI TJX W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 |
ID | FETCH-LOGICAL-c812-55f97e6517b1f7561b12b02dbc826341a0bf1bc4e6a60c0f5e0e6af057b8f1f93 |
ISSN | 0195-668X |
IngestDate | Thu Sep 12 18:58:09 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c812-55f97e6517b1f7561b12b02dbc826341a0bf1bc4e6a60c0f5e0e6af057b8f1f93 |
ParticipantIDs | crossref_primary_10_1093_ehjci_ehaa946_3002 |
PublicationCentury | 2000 |
PublicationDate | 2020-11-01 |
PublicationDateYYYYMMDD | 2020-11-01 |
PublicationDate_xml | – month: 11 year: 2020 text: 2020-11-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | European heart journal |
PublicationYear | 2020 |
SSID | ssj0008616 |
Score | 2.3845901 |
Snippet | Abstract
Background
ST-elevation myocardial infarction (STEMI) mostly occurs as a result of vulnerable coronary artery plaque rupture. Constituting... |
SourceID | crossref |
SourceType | Aggregation Database |
Title | The association between statin pre-treatment and LDL Levels on the rate of STEMI presentation: data from the ACS Israeli Survey (ACSIS) 2008–2018 |
Volume | 41 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lj9MwEICtaldCXBBP8dYcOICidPOwnYQbWtgHark0SL1FcWprF-22qLQcOPEf9qfwj_aXMGM7aYqKxHKpIje1mswnz8MzHsZe6TjV-M0snHGJDgrPZqFKjAoRlpprIerUnlMw_iRPPvOPUzEdDH71spbWKzVsfuysK_kfqeIYypWqZG8g2W5SHMBrlC9-ooTx859lXG_eb5d0RVVClB2-1OF2Ivno_SgYUZpQu0kQ0EkRtnClRIHQL9piJJvxQfmjvQqUw0lw-m1Z64tzXHCW3222TY6jpxMKLlCOQ5s7kaLGz3dG_amD9iroP56Nk_ueIt0-yXiBPvzFVrh2Ul-u3VA57AzwCXXrvNS2K63XJT6GgQ5r3MUwfFizEKGUtskwaiW_FKObXEh32GS7VvO4x6Tte2qDqFWyUxu4k7L02ZfG8nFW1wWXwzSKko32a3f8_1CKXaqi26RPKztL5eeoUnuA6X6Cqxstq8fTTV5RLm2_3e6RfKUWznFg5zjo_4-eNdQza8q77I73R-Cdg-seG-j5fXZr7DMuHrArZAx6jIFnDBxjsMUYIGOAjIFjDPB25AaIMVgYsIxBn7G3QIQBEWbvRJbAEwaOMHht-XoDRNf1zyvi6iErjz6Uhyehb-QRNjm12hCmyLQUcaZik6HBruJERclMNejbohVVR8rEquFa1jJqIiN0hJcGPQmVm9gU6SO2N1_M9WMGqC64lFmk0U3n0hSKLOQsM8IoI5QonrCgfZ_VV3dcS_V3CT690d3P2O0Nu8_Z3mq51i_QIl2pl5aA33oFims |
link.rule.ids | 315,783,787,27936,27937 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+association+between+statin+pre-treatment+and+LDL+Levels+on+the+rate+of+STEMI+presentation%3A+data+from+the+ACS+Israeli+Survey+%28ACSIS%29+2008%E2%80%932018&rft.jtitle=European+heart+journal&rft.au=Dadon%2C+Z&rft.au=Moriel%2C+M&rft.au=Samuel%2C+T.Y&rft.au=Steinmetz%2C+Y&rft.date=2020-11-01&rft.issn=0195-668X&rft.eissn=1522-9645&rft.volume=41&rft.issue=Supplement_2&rft_id=info:doi/10.1093%2Fehjci%2Fehaa946.3002&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_ehjci_ehaa946_3002 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0195-668X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0195-668X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0195-668X&client=summon |